|
Bob, a Carticept board member since October 2005, joined Domain as a Kauffman Fellow in 1996 and became a Partner in 2000. Present board memberships other than Carticept include Achaogen, Acureon Pharmaceuticals, Apnex Medical, Evoke Pharma, Glaukos, Lipothera, Novalar Pharmaceuticals, OmniSonics Medical Technologies and TargetRx. Past board memberships include ESP Pharma (acquired by Protein Design Labs, Inc.), Proxima Therapeutics (acquired by Cytyc Corporation), Onux Medical (acquired by C.R. Bard), NovaCardia (acquired by Merck), and Esprit Pharma (acquired by Allergan). Bob was also responsible for Domain's investment in IntraLase (acquired by Advanced Medical Optics, Inc.). Additionally, Bob served as a Founding board member for Kauffman Fellows Program and serves as an Advisory board member for Montagu Newhall Associates, Okapi Ventures, The Medical Industry Group of the NVCA and The Sulpizio Family Cardiovascular Center. From 1997-1998, Bob served as the Chief Operating Officer of Small Molecule Therapeutics, a Domain portfolio company subsequently purchased by Morphochem AG. From 1992 to 1995, Bob was with Pharmacia Biotech in sales. Prior to joining Pharmacia, Bob held a research position at Somatogen, a company developing a recombinant blood substitute that was subsequently bought by Baxter. While attending business school, Bob worked with MedVest, an early-stage venture group in Washington, D.C. Bob received his BA from Middlebury College and his MBA from Darden School of Business Administration, University of Virginia. | 